Tag Archive: monoclonal antibody therapy

Jan 30

Combination Products: What’s New?

A monoclonal antibody combined with a therapeutic drug. An EpiPen®. A drug packaged with its delivery device. All of these are examples of combination products. A combination product, according to the FDA, is “a product composed of any combination of a drug and a device; a biological product and a device; a drug and a …

Continue reading »

Nov 29

Fifth China Medicinal Biotech Forum – Conference Recap

I recently returned from the Fifth China Medicinal Biotech Forum held in Beijing, China from 07-09 November 2011.  The purpose of this conference was to update graduate students in China on the latest trends in biotechnology.  This forum also allowed scientists from Europe, Australia, Japan, US, and South America to collaborate with Chinese colleagues at …

Continue reading »

Mar 14

2010 New Drug Approvals

The U.S. FDA’s Center for Drug Evaluation and Research (CDER) approved 21 new products in 2010 – slightly less than the previous year’s 24 – plus 5 biologics approved by CBER. In light of the FDA’s continued focus on drug safety, I am not surprised that the number isn’t higher. A full list of approvals can be found here.

While the list isn’t long, a few new products stand out to me.

Jun 29

Cato at the Cancer Vaccines Meeting

This week, Cato Research is attending the Cancer Vaccines meeting in Cambridge, MA on 29 and 30 June.  The conference is the first meeting dedicated to progressing cancer vaccines to market and will feature 21 of the world’s leading experts in oncology and cancer vaccines.  The cutting-edge agenda addresses the key developmental challenges in order …

Continue reading »

May 12

Approval of Therapeutic Cancer Vaccines

Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  Provenge is the first cancer treatment that utilizes the strength of the patient’s own immune system to fight tumors.  This approval could mark the beginning of a …

Continue reading »